| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $725,290 | 3 | 27 |
Sells | $1,485,681 | 8 | 73 |
| Freedman Lori | Chief Admin. and Legal Officer | 3 | $725,290 | 0 | $0 | $725,290 |
| Driscoll Michael Joseph | director | 0 | $0 | 1 | $127,535 | $-127,535 |
| Gillheeney Gary S. | President and CEO | 0 | $0 | 7 | $1.36M | $-1.36M |
Organogenesis Holdings Inc., a regenerative medicine company develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane wound covering in which viable cells growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, and cytokines; NuShield, a wound covering tissue includes both amnion and chorion membranes for spongy/intermediate layer intact; PuraPly , a antimicrobial barrier that enables conformability and fluid drainage; and Novachor, an amniotic membrane wound covering in which viable cells, growth factors/cytokines, and ECM proteins are preserved. Its surgical and sports medicine products comprise NuCel, a dehydrated placental tissue surgically applied to the target tissue to support native healing; ReNu, a cryopreserved suspension used to support healing of soft tissues; and FiberOS and OCMP used as a bone void filler primarily in orthopedic and neurosurgical applications. The company's pipeline products include PuraPly XT and PuraPly MZ to treat chronic, acute, and open wounds; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; and TransCyte, a bioengineered tissue for the treatment of partial thickness burns. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician office through direct sales force and independent agencies. The company was founded in 1985 and is headquartered in Canton, Massachusetts.
Over the last 12 months, insiders at Organogenesis Holdings Inc. have bought $725,290 and sold $1.49M worth of Organogenesis Holdings Inc. stock.
On average, over the past 5 years, insiders at Organogenesis Holdings Inc. have bought $10.52M and sold $35.14M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Freedman Lori (Chief Admin. and Legal Officer) — $725,290.
The last purchase of 9,022 shares for transaction amount of $26,949 was made by Freedman Lori (Chief Admin. and Legal Officer) on 2025‑06‑06.
| 2025-06-06 | Freedman Lori | Chief Admin. and Legal Officer | 9,022 0.007% | $2.99 | $26,949 | +20.96% | ||
| 2025-06-05 | Freedman Lori | Chief Admin. and Legal Officer | 142,379 0.1132% | $2.91 | $413,625 | +27.08% | ||
| 2025-06-04 | Freedman Lori | Chief Admin. and Legal Officer | 100,863 0.0785% | $2.82 | $284,716 | +27.10% | ||
| 2025-03-04 | Sale | Driscoll Michael Joseph | director | 25,000 0.02% | $5.10 | $127,535 | -15.82% | |
| 2024-12-16 | Sale | Gillheeney Gary S. | President and CEO | 5,585 0.0042% | $3.49 | $19,492 | +1.69% | |
| 2024-12-13 | Sale | Gillheeney Gary S. | President and CEO | 55,615 0.0414% | $3.36 | $186,866 | +6.18% | |
| 2024-12-12 | Sale | Gillheeney Gary S. | President and CEO | 43,359 0.0332% | $3.55 | $153,924 | +2.27% | |
| 2024-12-11 | Sale | Gillheeney Gary S. | President and CEO | 157,448 0.1179% | $3.64 | $573,111 | -1.50% | |
| 2024-12-10 | Sale | Gillheeney Gary S. | President and CEO | 58,525 0.044% | $3.64 | $213,031 | -1.90% | |
| 2024-12-09 | Sale | Gillheeney Gary S. | President and CEO | 41,052 0.031% | $3.52 | $144,503 | +3.14% | |
| 2024-12-06 | Sale | Gillheeney Gary S. | President and CEO | 18,416 0.0139% | $3.65 | $67,218 | -1.90% | |
| 2024-01-10 | Sale | ERANI ALBERT | 10 percent owner | 17,972 0.0143% | $4.28 | $76,875 | -28.43% | |
| 2024-01-09 | Sale | ERANI ALBERT | 10 percent owner | 197,921 0.1518% | $4.37 | $863,985 | -32.56% | |
| 2023-04-12 | Sale | ERANI ALBERT | 10 percent owner | 50,000 0.0384% | $2.07 | $103,545 | +43.69% | |
| 2023-04-12 | Sale | ERANI ALBERT | 10 percent owner | 25,000 0.0192% | $2.07 | $51,773 | +43.69% | |
| 2022-11-21 | KATZ MICHAEL W | director | 3,000 0.0023% | $2.56 | $7,680 | +0.77% | ||
| 2022-11-18 | KATZ MICHAEL W | director | 3,000 0.0023% | $2.57 | $7,710 | +1.35% | ||
| 2022-08-12 | Leibowitz Arthur S | 3,000 0.0023% | $4.75 | $14,265 | -38.14% | |||
| 2022-08-12 | Driscoll Michael Joseph | 5,000 0.0039% | $4.80 | $24,000 | -38.14% | |||
| 2022-06-09 | Sale | Wisdom Starr | 29,669 0.0219% | $4.89 | $145,081 | -40.39% |
| Gillheeney Gary S. | President and CEO | 3039194 2.3958% | $13.28M | 0 | 19 | |
| Freedman Lori | Chief Admin. and Legal Officer | 846459 0.6673% | $3.7M | 3 | 0 | |
| Driscoll Michael Joseph | director | 166879 0.1316% | $729,261.23 | 1 | 1 | <0.0001% |
| Ades Alan A. | 59836745 47.1698% | $261.49M | 5 | 2 | +41.74% | |
| NUSSDORF GLENN H | 59448027 46.8633% | $259.79M | 6 | 2 | +28.07% | |
| GN 2016 Organo 10-Year GRAT u/a/d September 30, 2016 | 10 percent owner | 59448027 46.8633% | $259.79M | 1 | 0 | <0.0001% |
| Albert Erani Family Trust dated 12/29/2012 | 10 percent owner | 59432133 46.8508% | $259.72M | 0 | 4 | |
| Erani Dennis | 59248027 46.7057% | $258.91M | 0 | 3 | ||
| Wisdom Starr | 59248027 46.7057% | $258.91M | 0 | 10 | ||
| ERANI ALBERT | 10 percent owner | 59007134 46.5158% | $257.86M | 0 | 8 | |
| Avista Capital Managing Member IV, LLC | 29924515 23.5897% | $130.77M | 18 | 0 | +53.22% | |
| Avista Acquisition Corp. | 10 percent owner | 5692500 4.4874% | $24.88M | 0 | 2 | |
| MARKISON BRIAN A | director | 775000 0.6109% | $3.39M | 2 | 0 | |
| MACKIE WAYNE D | director | 200000 0.1577% | $874,000.00 | 9 | 0 | +33.4% |
| KATZ MICHAEL W | director | 76382 0.0602% | $333,789.34 | 15 | 0 | <0.0001% |
| Leibowitz Arthur S | 70854 0.0559% | $309,631.98 | 3 | 0 | +69.17% | |
| Montecalvo Antonio S. | Vice President, Health Policy | 44289 0.0349% | $193,542.93 | 0 | 1 |
$12,681,496 | 70 | 20.90% | $1.05B | |
$218,350,131 | 64 | 16.68% | $231.89M | |
Organogenesis Holdings Inc. (ORGO) | $129,489,279 | 57 | 26.09% | $554.35M |
$33,884,330 | 45 | 12.58% | $472.23M | |
$97,642,477 | 41 | -10.58% | $593.18M | |
$102,493,771 | 40 | 22.98% | $999.72M | |
$6,021,989 | 30 | -0.17% | $417.18M | |
$32,539,771 | 28 | 33.37% | $228.19M | |
$6,506,230 | 27 | -16.20% | $774.69M | |
$25,034,841 | 20 | 9.38% | $124.2M | |
$1,843,996 | 10 | 22.92% | $972.01M | |
$758,061 | 9 | 60.03% | $167.5M | |
$26,633,903 | 9 | 42.23% | $1B | |
$1,683,154 | 8 | 46.59% | $644.98M | |
$179,515 | 7 | 1.51% | $376.15M | |
$543,932 | 6 | -22.03% | $571.57M | |
$138,873 | 5 | 1.23% | $64.46M | |
$514,533 | 5 | 29.58% | $1.19B | |
$5,003,136 | 1 | -14.58% | $277.32M |
| Increased Positions | 73 | +53.28% | 11M | +18.05% |
| Decreased Positions | 60 | -43.8% | 4M | -5.86% |
| New Positions | 29 | New | 3M | New |
| Sold Out Positions | 13 | Sold Out | 528,473 | Sold Out |
| Total Postitions | 150 | +9.49% | 68M | +12.19% |
| Soleus Capital Management, L.P. | $65,920.00 | 9.83% | 12.48M | +645,000 | +5.45% | 2024-12-31 |
| Morgan Stanley | $62,465.00 | 9.32% | 11.83M | -139,157 | -1.16% | 2024-12-31 |
| Blackrock, Inc. | $27,226.00 | 4.06% | 5.16M | -119,618 | -2.27% | 2025-03-31 |
| Vanguard Group Inc | $18,954.00 | 2.83% | 3.59M | -82,636 | -2.25% | 2024-12-31 |
| Acadian Asset Management Llc | $16,287.00 | 2.43% | 3.08M | +65,655 | +2.17% | 2024-12-31 |
| Dimensional Fund Advisors Lp | $14,727.00 | 2.2% | 2.79M | +442,772 | +18.87% | 2024-12-31 |
| Deutsche Bank Ag | $12,935.00 | 1.93% | 2.45M | -2M | -49.42% | 2024-12-31 |
| Geode Capital Management, Llc | $9,175.00 | 1.37% | 1.74M | -7,694 | -0.44% | 2024-12-31 |
| State Street Corp | $8,208.00 | 1.22% | 1.55M | +94,744 | +6.49% | 2024-12-31 |
| Aqr Capital Management Llc | $8,037.00 | 1.2% | 1.52M | -1M | -43.84% | 2024-12-31 |